INDUCTION AND SUPPRESSION OF NEOANGIOGENESIS

描述：(改编自申请人的摘要)。这个项目将 研究一种最近被描述的蛋白质Cyr61诱导 定位血管新血管生成，并开发检测方法 筛选该活性的特异性抑制剂。新血管生成起到了 在伤口愈合中起关键作用，也是肿瘤生长和 转移。因此，Cyr61的治疗性抑制剂可能是有市场的 抗癌药物。第一阶段的具体目标如下：(1) 证明该蛋白在体内诱导新生血管生成；(2) 基于该蛋白预期功能的体外检测方法的建立 促进毛细血管前体细胞迁移的能力，可以 用于快速筛选候选抗血管生成药物；(3) 鉴定缺乏该蛋白的哺乳动物细胞系并利用它们 证明Cyr61有能力促进肿瘤相关肿瘤的生长 体内的血管构筑。 建议的商业应用：不可用

DESCRIPTION: (Adapted from the Applicant's Abstract). This project will examine the ability of a recently described protein, Cyr61, to induce localized vascular neoangiogenesis and to develop assays with which to screen specific inhibitors of this activity. Neoangiogenesis plays a critical role in wound healing and also is necessary for tumor growth and metastasis. Thus, therapeutic inhibitors of Cyr61 could be marketable anti-cancer drugs. The specific aims of phase I are the following: (1) demonstration that this protein induces neoangiogenesis in vivo; (2) establishment of an in vitro assay based on this protein's anticipated ability to promote the migration of capillary progenitor cells that can be used to screen rapidly for candidate anti-neoangiogenesis drugs; (3) to identify mammalian cell lines deficient in this protein and to use them to demonstrate the ability of Cyr61 to promote the growth of tumor associated vasculature in vivo. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE